In addition to the known relevant clinicopathological prognostic factors like e.g. large tumor size (>2 cm), lymph node metastasis or HER2 gene amplification [5], [6], genomic multigene assays can be used as additional tools to assist treatment decisions and to avoid under- or overtreatment by estimation of the biological tumor behavior [7], [8]. Here, ERBB2 is linked to neoplasm.